Difference between revisions of "Part:BBa K1795024"
Liu Jiankai (Talk | contribs) (→iGEM2022_Nanjing-China Experiment) |
Liu Jiankai (Talk | contribs) (→iGEM2022_Nanjing-China Experiment) |
||
| Line 15: | Line 15: | ||
==iGEM2022_Nanjing-China Experiment== | ==iGEM2022_Nanjing-China Experiment== | ||
| − | |||
<div> | <div> | ||
<b>Group: Nanjing-China 2022</b> | <b>Group: Nanjing-China 2022</b> | ||
| Line 21: | Line 20: | ||
<b>Author: Jiankai Liu</b> | <b>Author: Jiankai Liu</b> | ||
<br><br> | <br><br> | ||
| − | + | [[Image:Nanjing-China-recombination-device-Atox1.jpeg|400px|thumb|right|Homologous recombination device design]] | |
<p> | <p> | ||
We believe that there are two modes to improve part. One is to optimize the performance of the existing functions of part, and the other is to expand its application scenarios. Here we chose the latter to implement the improvement of BBa_K1795024. | We believe that there are two modes to improve part. One is to optimize the performance of the existing functions of part, and the other is to expand its application scenarios. Here we chose the latter to implement the improvement of BBa_K1795024. | ||
Latest revision as of 07:16, 12 October 2022
KanR Operon under R0010
Provides Kanamycin Resistance to the cell under the Promoter R0010.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
iGEM2022_Nanjing-China Experiment
Group: Nanjing-China 2022
Author: Jiankai Liu
We believe that there are two modes to improve part. One is to optimize the performance of the existing functions of part, and the other is to expand its application scenarios. Here we chose the latter to implement the improvement of BBa_K1795024.
The existing part BBa_K1795024 provides Kanamycin resistance to the cell under the Promoter R0010. In the absence of LacI protein and CAP protein, this part promotes KanR transcription. In the presence of LacI protein and CAP protein, this part inhibits KanR transcription.
Combined with our own project requirements, we hope to engineer it into a reporter gene of homologous recombination. We kept the KanR coding region and removed its initiation codon so that KanR shares the same initiation codon with BpfA. Then Kanamycin resistance can be used as the basis to judge whether the strain is recombinant that displays silver-binding protein. The recombinant is able to grow on the plate with kanamycin, only if the goal sequence and KanR are recombined to the C-terminal of BpfA successfully.